CN107595934A - A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine - Google Patents
A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine Download PDFInfo
- Publication number
- CN107595934A CN107595934A CN201710871251.0A CN201710871251A CN107595934A CN 107595934 A CN107595934 A CN 107595934A CN 201710871251 A CN201710871251 A CN 201710871251A CN 107595934 A CN107595934 A CN 107595934A
- Authority
- CN
- China
- Prior art keywords
- walnut grouts
- walnut
- polyphenol
- purified
- purposes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000009496 Juglans regia Nutrition 0.000 title claims abstract description 66
- 235000020234 walnut Nutrition 0.000 title claims abstract description 66
- 235000013824 polyphenols Nutrition 0.000 title claims abstract description 54
- 150000008442 polyphenolic compounds Chemical class 0.000 title claims abstract description 52
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 27
- 239000003814 drug Substances 0.000 title claims abstract description 25
- 244000052616 bacterial pathogen Species 0.000 title abstract 3
- 240000007049 Juglans regia Species 0.000 title description 2
- 241000758789 Juglans Species 0.000 claims abstract description 67
- 235000009200 high fat diet Nutrition 0.000 claims abstract description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 38
- 241000304886 Bacilli Species 0.000 claims description 22
- 235000019441 ethanol Nutrition 0.000 claims description 13
- 241000692822 Bacteroidales Species 0.000 claims description 9
- 239000011347 resin Substances 0.000 claims description 9
- 229920005989 resin Polymers 0.000 claims description 9
- 239000000706 filtrate Substances 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 7
- 239000000523 sample Substances 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 241001112693 Lachnospiraceae Species 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 239000002702 enteric coating Substances 0.000 claims description 6
- 238000009505 enteric coating Methods 0.000 claims description 6
- 239000010410 layer Substances 0.000 claims description 6
- 238000010828 elution Methods 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 241000305071 Enterobacterales Species 0.000 claims description 4
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 claims description 4
- 238000011068 loading method Methods 0.000 claims description 4
- 229920000642 polymer Polymers 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 239000012488 sample solution Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- -1 vinyl acetate phthalate ester Chemical class 0.000 claims description 4
- 241000731710 Allobaculum Species 0.000 claims description 3
- 241000193833 Bacillales Species 0.000 claims description 3
- 241000606125 Bacteroides Species 0.000 claims description 3
- 241001141113 Bacteroidia Species 0.000 claims description 3
- 241001135755 Betaproteobacteria Species 0.000 claims description 3
- 241001112696 Clostridia Species 0.000 claims description 3
- 241001112695 Clostridiales Species 0.000 claims description 3
- 241000588921 Enterobacteriaceae Species 0.000 claims description 3
- 241001148568 Epsilonproteobacteria Species 0.000 claims description 3
- 241000609971 Erysipelotrichaceae Species 0.000 claims description 3
- 241001081257 Erysipelotrichales Species 0.000 claims description 3
- 241001081259 Erysipelotrichia Species 0.000 claims description 3
- 241001183186 Fusobacteriaceae Species 0.000 claims description 3
- 241001183197 Fusobacteriales Species 0.000 claims description 3
- 241001183200 Fusobacteriia Species 0.000 claims description 3
- 241000605909 Fusobacterium Species 0.000 claims description 3
- 241000192128 Gammaproteobacteria Species 0.000 claims description 3
- 241001248432 Helicobacteraceae Species 0.000 claims description 3
- 241000125969 Lachnoclostridium Species 0.000 claims description 3
- 241000909283 Negativicutes Species 0.000 claims description 3
- 241000843248 Oscillibacter Species 0.000 claims description 3
- 241000606752 Pasteurellaceae Species 0.000 claims description 3
- 241001464921 Phascolarctobacterium Species 0.000 claims description 3
- 241000692844 Prevotellaceae Species 0.000 claims description 3
- 241000113606 Ruminiclostridium Species 0.000 claims description 3
- 241000095588 Ruminococcaceae Species 0.000 claims description 3
- 241000909295 Selenomonadales Species 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000000284 extract Substances 0.000 claims description 3
- 230000002829 reductive effect Effects 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000945 filler Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- 239000000314 lubricant Substances 0.000 claims description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 claims description 2
- 229940117841 methacrylic acid copolymer Drugs 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims description 2
- 238000011084 recovery Methods 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 239000002904 solvent Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000375 suspending agent Substances 0.000 claims description 2
- 239000003643 water by type Substances 0.000 claims description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 claims 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims 1
- 229920006243 acrylic copolymer Polymers 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 238000009736 wetting Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 abstract description 13
- 150000003626 triacylglycerols Chemical class 0.000 abstract description 12
- 235000013305 food Nutrition 0.000 abstract description 11
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 5
- 235000005911 diet Nutrition 0.000 abstract description 4
- 230000037213 diet Effects 0.000 abstract description 4
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract description 2
- 239000013589 supplement Substances 0.000 abstract description 2
- 238000011552 rat model Methods 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 23
- 210000001035 gastrointestinal tract Anatomy 0.000 description 15
- 230000037396 body weight Effects 0.000 description 12
- 108010028554 LDL Cholesterol Proteins 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 7
- 208000008589 Obesity Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 235000020824 obesity Nutrition 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 238000010171 animal model Methods 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 244000144730 Amygdalus persica Species 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 150000002989 phenols Chemical class 0.000 description 3
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 3
- 229960002855 simvastatin Drugs 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 241000723418 Carya Species 0.000 description 2
- 240000004875 Carya cathayensis Species 0.000 description 2
- 108010023302 HDL Cholesterol Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000758791 Juglandaceae Species 0.000 description 2
- 235000013757 Juglans Nutrition 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000019498 Walnut oil Nutrition 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 2
- 244000005709 gut microbiome Species 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000008170 walnut oil Substances 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 102000005606 Activins Human genes 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 241001002570 Annamocarya Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 244000068645 Carya illinoensis Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 244000184861 Juglans nigra Species 0.000 description 1
- 241000276305 Juglans sigillata Species 0.000 description 1
- VAYOSLLFUXYJDT-RDTXWAMCSA-N Lysergic acid diethylamide Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N(CC)CC)C2)=C3C2=CNC3=C1 VAYOSLLFUXYJDT-RDTXWAMCSA-N 0.000 description 1
- 241000282320 Panthera leo Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 240000008199 Rhododendron molle Species 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 230000002019 anti-mutation Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229940099352 cholate Drugs 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229940074391 gallic acid Drugs 0.000 description 1
- 235000004515 gallic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 235000008935 nutritious Nutrition 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 238000012847 principal component analysis method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000012175 pyrosequencing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229930000044 secondary metabolite Natural products 0.000 description 1
- 229940103114 simvastatin 40 mg Drugs 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 239000010902 straw Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000000052 vinegar Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a kind of walnut grouts polyphenol purified to prepare the purposes in treating intestinal bacilli illness medicine, and the intestinal bacilli illness is to cause part flora relative abundance to significantly reduce by high fat diet to dramatically increase with part flora relative abundance.The walnut grouts polyphenol purified of the present invention is it is observed that the rat model result of high lipid food induced hyperlipidemia shows, supplement walnut grouts polyphenol purified can adjust the enteric flora disturbance as caused by diet, it can significantly modify the composition of gut flora, gut flora unbalance in vivo is set to tend to be normal, and then the fat blood lipids index caused by regulation enteric flora disturbance caused by high fat diet, it can obviously reduce the content of serum cholesterol, triglycerides, low-density lipoprotein.
Description
Technical field
The invention belongs to pharmaceutical technology field, and in particular to walnut grouts polyphenol purified is preparing treatment gut flora mistake
Adjust the purposes in medicine.
Background technology
As the development of human society and the extreme enrichment of material life, problem of obesity are more and more general in the world
Time, either developed country or developing country, fat incidence are all presented the trend substantially risen, problem of obesity into
Pretty figure is not only influenceed for the public health problem obesity that the world attractes attention, it is often more important that easy induced Diabetic, cardiovascular disease
The diseases such as disease, fatty liver and cancer, turn into one of disease of greatest concern of puzzlement human health.Gut flora belongs to the mankind and is total to
Raw microorganism, a kind of dynamic balance state is in body, forms and mutually adjust, condition each other and the system of interdependence,
It is described as " the second genome of human body.Under normal circumstances, gut flora remains poised state, enteron aisle with human body internal and external environment
Normal flora in human activin immune system, help human consumption and absorb nutrition, resist the invasion and generation of external pathogen
Important metabolite and bioactive ingredients etc. play the role of many irreplaceable.And there is research to show gut flora
Fat metabolism can be controlled, trigger systemic chronic low grade inflammation, induce obesity and insulin resistance as environmental factor.
Constantly there is research to confirm that change of the high fat diet to intestinal microflora has a major impact, and normal intestinal flora may join
With inducing generation fat caused by diet.Therefore, normalization is allowed to by adjusting gut flora, is to prevent and treat such as fertilizer
One of important research directions of disease such as fat, hyperlipidemia.
Walnut system Juglandaceae (Juglandaceae) Juglans (Juglan Linn.), hickory (Carya), edge walnut
Belong to the magaphanerophytes such as (Annamocarya), its fruit with mainly having J.regia, J.sigillata, J.nigra,
J.cathayensis, C.cathayensis, C.illinoensis, A.sinensis etc..Walnut is a kind of collection protein, fat
The excellent dry fruit based food of the nutritional factors such as fat, cellulose, vitamin, nutritious, economic value is high.Motherland's medical science
Think that walnut is warm-natured, sweet, nontoxic, have stomach invigorating, enrich blood, moistening lung, repose and other effects, walnut kernel is recorded in Chinese Pharmacopoeia.Core
Peach is partly used to squeeze walnut oil in addition to directly eating as oil plant.Walnut grouts are that walnut kernel squeezes the pair after walnut oil
Product, it contains abundant phenolic compound (6.75%) and good protein.In recent years, walnut cake protein matter is because of its product
With different physiological roles such as anti-oxidant, anti-cardiovascular disease, anti-obesity, anti-diabetics, part walnut grouts are as production core
The raw material of peach polypeptide, in terms of being widely used in medical research.But the phenolic compound that walnut grouts are rich in does not cause too
More attention, most of walnut grouts still use as animal feed at present, and added value is relatively low.
Phenolic compound is widely present in plant, is one of mostly important secondary metabolites of plant kingdom, and it is every
Physiology and trophic function confirm by numerous studies, development trend and has a extensive future.Purposefully often taken the photograph in diet
Chronic disease risk caused by food of the food rich in polyphenol active component can reduce various free radicals, such as angiocardiopathy, cancer
Disease, heart disease etc..For polyphenol compound because being naturally occurring in various plants, resource is extensive, and physiological function is powerful, application prospect
It is wide, and the deep extensive concern by domestic and foreign scholars.At present, plant polyphenol is generally used for medical industry and is used as health products, anti-
Only treat the medicines such as angiocardiopathy, and the product such as antioxidant of cosmetics and skincare product, food service industry.
The experiment of many antioxidation in vitro is it has proven convenient that the excellent anti-oxidant and radical scavenging activity of walnut polyphenol, to freedom
The large biological molecule damage that base induces plays a protective role, and maintains the mobility of cell membrane and the configuration conformation of protein, prevents
DNA (DNA) fracture of radiation-actuate, has the effect such as anti-mutation, antitumor, anticancer, anti-aging, reducing blood lipid.
The purposes of the purposes of walnut polyphenol, particularly exploitation as the walnut grouts polyphenol of oil expression byproduct is further developed, it is not only former
Expect that cost is low, can also improve the added value of walnut grouts, and be also instantly slow as target spot preventing and treating metabolic using gut flora
One of study hotspot of venereal disease.
The content of the invention
It is an object of the invention to provide a kind of walnut grouts polyphenol purified to prepare treatment intestinal bacilli illness medicine
In purposes.
The object of the present invention is achieved like this：Walnut grouts polyphenol purified is preparing treatment intestinal bacilli illness medicine
In purposes, the intestinal bacilli illness is that part flora relative abundance significantly reduces and part flora as caused by high fat diet
Relative abundance dramatically increases.
The walnut grouts polyphenol purified of the present invention shows through high lipid food Induced Obesity in Rats model experiment results, supplements
Walnut grouts polyphenol purified can reverse such as norank of Bacteroidales S24- of the flora caused by high fat diet
7group、unclassified of Lachnospiraceae、Allobaculum、Ruminiclostridium、
Bacteroidales S24-7 group、Ruminococcaceae、Prevotellaceae、Erysipelotrichaceae
Veillonellacea、Helicobacteraceae、Clostridiales、Clostridia、Erysipelotrichales、
The abundance such as Campylobacteriales, Erysipelotrichia and/or Epsilonproteobacteria significantly reduce and
Bacteroides、Escherichia-Shigella、Phascolarctobacterium、Lachnoclostridium、
Oscillibacter、Fusobacterium、norank of Lachnospiraceae、Enterobacteriaceae、
bacteroidales、Acidaminnococcaceae、Fusobacteriaceae、Pasteurellaceae、
Enterobacteriale、selenomonadales、Fusobacteriales、Bacillales、Bacteroidia、
The abundance such as Gammaproteobacteria, Negativicutes, betaproteobacteria and/or Fusobacteriia
The intestinal bacilli illness being substantially increased result in, the composition of gut flora is can significantly modify, tend to gut flora unbalance in vivo
Normally, and then the Anomalous lipid metablism caused by enteric flora disturbance is adjusted, has significant drop to TC, TG, LDL-C of experimental animal
Low effect.The present invention walnut grouts polyphenol purified in walnut grouts after ethanol slightly carries, by alcohol extract through absolute ethyl alcohol
Precipitate polysaccharides and protein, so as to avoid causing macroreticular resin poisoning (more carbohydrate, protein in follow-up purge process
Cause macroporous resin adsorption ability to decline Deng impurity, or even disappear), purification efficiency is improved with this.Present invention treatment gut flora
Imbalance medicine includes the core and enteric coating layer for including walnut grouts polyphenol purified, and bag is protected by the enteric coating layer of enteric solubility
The core of the polyphenol purified of grouts containing walnut, walnut grouts polyphenol purified can be avoided to be dissolved in advance in hydrochloric acid in gastric juice, and ensured
Quick dissolving in the intestine, realize that enteral targets control release, so as to improve drug effect and reduce adverse reaction.
Brief description of the drawings
Fig. 1 is influence of the walnut grouts polyphenol purified to Induced by High Fat Diet in Rats body weight after experimental example modeling success；
Fig. 2 is warm in the group of category categorization levels for the 0th, 6,14 week each group intestine in rats microorganism after experimental example modeling success
Figure；
In Fig. 2：There is " " then to represent that temperature is less than 1.5 in grid.
Embodiment
The present invention is further illustrated with experimental example below in conjunction with the accompanying drawings, but the present invention is not subject in any way
Limitation, based on present invention teach that any changes and modifications made, belong to protection scope of the present invention.
Walnut grouts polyphenol purified of the present invention is preparing the purposes in treating intestinal bacilli illness medicine, the enterobacteriaceae
Group's imbalance is to cause part flora relative abundance to significantly reduce by high fat diet to dramatically increase with part flora relative abundance.
The significantly reduced part flora of relative abundance includes norank of Bacteroidales S24-7
group、unclassified of Lachnospiraceae、Allobaculum、Ruminiclostridium、
Bacteroidales S24-7group、Ruminococcaceae、Prevotellaceae、Erysipelotrichaceae
Veillonellacea、Helicobacteraceae、Clostridiales、Clostridia、Erysipelotrichales、
Campylobacteriales, Erysipelotrichia and/or Epsilonproteobacteria.
The part flora that the relative abundance dramatically increases include Bacteroides, Escherichia-Shigella,
Phascolarctobacterium、Lachnoclostridium、Oscillibacter、Fusobacterium、norank of
Lachnospiraceae、Enterobacteriaceae、bacteroidales、Acidaminnococcaceae、
Fusobacteriaceae、Pasteurellaceae、Enterobacteriale、selenomonadales、
Fusobacteriales、Bacillales、Bacteroidia、Gammaproteobacteria、Negativicutes、
Betaproteobacteria and/or Fusobacteriia.
The walnut grouts polyphenol purified is the extraction that walnut grouts are purified by flash after ethanol slightly carries through macroreticular resin
Thing, Determination of Polyphenols is no less than 70% by mass percentage in the walnut grouts polyphenol purified.
The preparation concrete operations of the walnut grouts polyphenol purified are as follows：
Walnut shell is cleaned, dry after crushed 20~40 mesh sieves, screenings is consolidated with 45~55% ethanol waters with liquid
Volume mass is than 40~60:1 under 75~80 DEG C of temperature conditionss, by 1~1.5h/ times refluxing extraction 1~2 time, merging filtrate；Will
Merging filtrate uses macroreticular resin by upper liquid sample pH value for 3.5~4.0,3.5~4.5mg/mL of sample solution mass concentration, loading stream
0.8~1.2BV/h of speed, 1.6~1.8BV of upper prop liquid product, eluant ethanol volume fraction 70~80%, elution flow rate 3~
4BV/h and elution volume are that 2.5~3.5BV is eluted, and it is pure that freeze-drying or spray drying obtain the walnut grouts polyphenol
Compound.
Concentration is the concentrate of 1mg/mL Solid contents after filtrate merges in the merging filtrate, and 1 is pressed in concentrate：0.1
~0.3 concentrate：The volume ratio of absolute ethyl alcohol is added into absolute ethyl alcohol, after stirring and evenly mixing stand 20~30min, then with
4500rpm rotating speeds centrifuge 10~20min and take supernatant, and macroreticular resin purification is proceeded as described above after supernatant recovery ethanol.
The formulation of the treatment intestinal bacilli illness medicine includes tablet, granule, capsule, dripping pill, vina or oral liquid.
The treatment intestinal bacilli illness medicine is by above-mentioned walnut grouts polyphenol purified and pharmaceutically acceptable carrier
Composition.
The pharmaceutically acceptable carrier include filler, adhesive, disintegrant, lubricant, suspending agent, wetting agent,
One kind or pharmaceutically acceptable any combination in solvent, surfactant, flavouring.
The treatment intestinal bacilli illness medicine includes the core comprising walnut grouts polyphenol purified and includes methyl-prop
Olefin(e) acid copolymer, HP-55, acetic acid hydroxypropyl methylcellulose succinate, CAP, poly-vinegar
The enteric coating layer of the component of polymer of one kind or any combination in sour ethene phthalate ester.
Component of polymer in the enteric coating layer be by methacrylic acid and selected from methyl acrylate, ethyl acrylate,
The methacrylic acid copolymer that the monomer of one kind or any combination in methyl methacrylate is formed.
Experimental example：
Obesity models are established using the SD male rats of feeding high lipid food, the walnut grouts polyphenol for observing the present invention is pure
Compound (WMP) is to the body weight and serum total cholesterol (TC) of obese model rat, triglycerides (TG), low-density lipoprotein
(LDL-C), the horizontal influence of liver weight, liver lipids.
1st, pharmacodynamic experiment
1) experimental animal and reagent
SPF levels male SD rat 60, male, 240~160g of body weight, reaches the limited public affairs of experimental animal by Hunan Si Laike scapes
Department provides.Quality certification number SYXK (Yunnan) K2011-0011.Basal feed is purchased from the limited public affairs of the double lion experimental animal feed technologies in Suzhou
Department.
Simvastatin Tablets (Hangzhou Mo Shadong pharmaceutical Co. Ltds), T-CHOL (TC), triglycerides (TG), high density fat
Albumen (HDL-C) kit and low-density lipoprotein (LDL-C) (Zhongsheng Beikong Biological Science ＆ Technology Co., Ltd.), millet straw turns ammonia
Enzyme (AST) and glutamic-pyruvic transaminase (ALT) (building up biotech inc purchased from Nanjing), other reagents are domestic point
Analyse pure.
The extraction and purifying of peach grouts polyphenol：Walnut grouts drying and crushing crosses 20 mesh sieves, weighs a certain amount of walnut grouts
Powder, according to concentration of alcohol 50%, 78 DEG C of Extracting temperature, solid-liquid ratio 1：50th, 80min Effect of Alcohol Extracting Procedureto Total extraction walnut grouts, are obtained
To walnut grouts polyphenol crude extract；Walnut grouts polyphenol crude extract is through HPD-100 macroporous resin purifications：Sample solution PH4.0, loading
Concentration is 4mg/ml, loading flow velocity is 1ml/min, the volume of sample solution is 1.8BV, eluant ethanol concentration is 75%, washed
De- flow velocity is 4BV/h, the volume of elution is 3BV.
The measure of polyphenol content：With Forint phenol method, using nutgall as reference substance, using absorbance as ordinate, gallic acid
Concentration is abscissa, draws standard curve and determines the content of polyphenol in walnut grouts extract, it is pure to obtain walnut grouts polyphenol
Determination of Polyphenols is 78.3% by mass percentage in compound (WMP).
2) animal processing method
SD male rats, 22 ± 2 DEG C of temperature, humidity 40~60%, each 12h, free water, ad lib are commonly raised round the clock
After expecting one week, 8 being selected at random and is only used as normal group (blank control group), feed basal feed, remaining rat is fed with high lipid food
After supporting 6 weeks, empty stomach 12h, the intraocular corner of the eyes takes hematometry TC, TG, and whether examination modeling succeeds.Modeling success after, at random modeling into
The rat of work(is divided into 5 groups, i.e. model group, positive drug group (simvastatin 40mg/kg), WMP high doses group (800mg/kg), WMP
Middle dose group (600mg/kg), WMP low dose groups (400mg/kg), normal group give isodose physiology salt with model group
Water, each group feed high lipid food.The equal ad lib water inlet of each group rat during experiment, by metering gastric infusion once daily,
Administered volume presses 0.5mL/100g.An empty body weight measure is carried out during experiment weekly, weekly set time progress food-intake
With the measure of amount of drinking water.
High lipid food：10% sucrose, 15% albumen powder, 10% lard, 1.5% cholesterol, 1% Pig cholate, 0.5% food
Salt, 62% normal diet.
0,6, the 14 week excrement for taking rat in administration respectively, gut flora is carried out using 454 pyrosequencing techniques
Analysis, for successive administration after 14 weeks, water 12h is can't help in fasting, claims weight, body length, with 10% chloraldurate (1mL/kg, abdominal cavity note
Penetrate) anesthesia after, abdominal aortic blood, be stored at room temperature 60min, after blood clotting under 4 DEG C of low temperature with 2500~3000r/min from
Heart 10min, carefully suction out upper serum, dispense, it is to be measured to be placed in -20 DEG C of preservation, according to kit specification measure serum TC,
TG、LDL-C。
Experimental data represents, using the statistical software analyzing and processing datas of GraphPad Prism 5.0, own with (x ± s)
Data carry out one-way analysis of variance, are that difference tool is statistically significant with P ＜ 0.05.
2nd, to body weight and lipid result and analysis
1) influence for the rat body weight that WMP is induced high fat diet
After successive administration 14 weeks, body weight, Lee ' s indexes, fat weight are checked, the results showed that：Each group is big after being administered 14 weeks
As shown in figure 1, compared with normal group, the body weight of model group dramatically increases (p for the body weight of mouse, the change of lipschitz exponent<0.01), table
Reveal typical fat sign, increased weight 18.42%.Compared with model group, WMP groups (600mg/kg and 800mg/kg) are notable
The body weight of rat is reduced, body weight reduces 16.18%, 16.69%, 17.75% respectively, illustrates that WMP significantly improves high fat
The body weight of diet rat.
2) influence for the Serum Lipids in Experimental HypercholesterolemicRats that WMP is induced high fat diet
The change of the blood fat of each group rat is shown in Table 1 after being administered 14 weeks, compared with normal group, Induced by High Fat Diet in Rats serum
TC, TG, LDL-C pole dramatically increase (P<0.01), illustrate that WMP is obviously promoted blood lipid level in rat body and risen.With
Model group is compared, WMP groups (400mg/kg, 600mg/kg, 800mg/kg) and Simvastatin group, significantly reduce serum TC, TG,
LDL-C is horizontal, TC reduces 36.77% respectively, 31.84%, 30.78%, 30.9%, TG reduce 81.13% respectively,
61.48%th, 82.51%, 80.31%.LDL-C reduces 55.1%, 39.94%, 40.77%, 45.89% respectively.Illustrate WMP
Play the role of significantly to adjust blood fat.
Influences of the table 1.WMP to Induced by High Fat Diet in Rats serum TC, TG, LDL-C, HDL-C
Note：Model group is compared with normal group, ###P<0.01；Simvastatin group, WMP groups are compared with model group, * * P<
0.05, * * * P<0.01.
3rd, result and analysis are influenceed on gut flora
Gather experimental rat normal group (NG), model group (MG), the 0th, 6, the 14 of WMP high doses group (hereinafter referred to as WMP)
The rat excrement in week, the gut flora of different groups and different time is subjected to variance analysis.
1) the Alpha diversity of sample compares
This experimental result finds that in this 3 different time points, the community diversity of model group was less than normal group, at 6 weeks
Shannon and simpson index differentials most significantly (P<0.001 or P<0.05), WMP groups are compared with model group, Shannon indexes
Rise, Simpson index decreaseds, at 14 weeks, difference was maximum, but there are no significant difference.The change of intestinal microflora abundance
Change in the assessment of bacterial abundance, mainly uses Ace indexes in environmental samples
With Chao indexes.Ace indexes or Chao indexes are bigger, illustrate that group's abundance is higher, model group compared with normal group,
Ace indexes have declined with Chao indexes, but there was no significant difference；Compared with model group, Ace indexes refer to WMP groups with Chao
Number rises, but compares that there was no significant difference between 3 groups.Result above shows, compared with normal rats, model group rats intestines
There is diversity reduction in road bacterium and bacterial gene abundance changes, and is obtained to WMP rear intestinal microbial diversities a certain degree of
Improve.
Influences of the WMP of table 2 to Induced by High Fat Diet in Rats intestine microbial diversity
2) sample Beta diversity compares
In order to further show sample room species diversity sex differernce, using principal component analysis (Principal
ComponentAnalysis method) shows the difference size of each sample room, and NG groups were all assembled 0,6,14 week 3 period
Together, principal component varies less, and MG groups each period principal component separate, 6 weeks to 14 weeks in PC3 and PC1 directions all
Change, it is close with MG group principal components during WMP groups 6 weeks, but assemble 14 weeks and NG, illustrate that WMP can make caused by high fat diet
Gut flora principal component is recovered towards normal group, have adjusted the unbalance of gut flora.
3) sample species difference is analyzed
As shown in Fig. 2 the thermal map in category level, group's composition distribution between the multiple samples of observable.It is broadly divided into two
Group, one group mainly has WMP6 groups and MG0, MG6, MG14 group to be collected as, and another group is assembled by WMP14 and NG0, NG6, NG14 group.
After being administered 14 weeks, the similitude for the gut flora height that NG14 group and WMP14 groups have, illustrate that WMP can make high fat diet
The intestinal bacilli illness of induction recovers normal.
Claims (10)
1. a kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine, the gut flora mistake
Tune is to cause part flora relative abundance to significantly reduce by high fat diet to dramatically increase with part flora relative abundance.
2. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 1,
It is characterized in that the significantly reduced part flora of relative abundance includes norank of Bacteroidales S24-
7group、unclassified of Lachnospiraceae、Allobaculum、Ruminiclostridium、
Bacteroidales S24-7group、Ruminococcaceae、Prevotellaceae、Erysipelotrichaceae
Veillonellacea、Helicobacteraceae、Clostridiales、Clostridia、Erysipelotrichales、
Campylobacteriales, Erysipelotrichia and/or Epsilonproteobacteria.
3. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 1,
It is characterized in that the part flora that dramatically increases of the relative abundance include Bacteroides, Escherichia-Shigella,
Phascolarctobacterium、Lachnoclostridium、Oscillibacter、Fusobacterium、norank of
Lachnospiraceae、Enterobacteriaceae、bacteroidales、Acidaminnococcaceae、
Fusobacteriaceae、Pasteurellaceae、Enterobacteriale、selenomonadales、
Fusobacteriales、Bacillales、Bacteroidia、Gammaproteobacteria、Negativicutes、
Betaproteobacteria and/or Fusobacteriia.
4. according to the walnut grouts polyphenol purified of claim 1,2 or 3 in treatment intestinal bacilli illness medicine is prepared
Purposes, it is characterised in that the walnut grouts polyphenol purified is that walnut grouts are purified by flash after ethanol slightly carries through macroreticular resin
Extract, Determination of Polyphenols is no less than 70% by mass percentage in the walnut grouts polyphenol purified.
5. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 4,
It is characterized in that the preparation concrete operations of the walnut grouts polyphenol purified are as follows：
Walnut shell is cleaned, dry after crushed 20~40 mesh sieves, screenings is accumulated with 45~55% ethanol waters with liquid solid
Mass ratio 40~60:1 under 75~80 DEG C of temperature conditionss, by 1~1.5h/ times refluxing extraction 1~2 time, merging filtrate；It will merge
Filtrate uses macroreticular resin by upper liquid sample pH value for 3.5~4.0,3.5~4.5mg/mL of sample solution mass concentration, loading flow velocity
0.8~1.2BV/h, upper prop liquid accumulate 1.6~1.8BV, eluant ethanol volume fraction 70~80%, 3~4BV/h of elution flow rate
It is that 2.5~3.5BV is eluted with elution volume, freeze-drying or spray drying obtain the walnut grouts polyphenol purified.
6. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 5,
It is characterized in that concentration is the concentrate of 1mg/mL Solid contents after filtrate merges in the merging filtrate, 1 is pressed in concentrate：
0.1~0.3 concentrate：The volume ratio of absolute ethyl alcohol is added into absolute ethyl alcohol, 20~30min is stood after stirring and evenly mixing, then
10~20min is centrifuged with 4500rpm rotating speeds and takes supernatant, macroreticular resin purification is proceeded as described above after supernatant recovery ethanol.
7. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 4,
It is characterized in that the treatment intestinal bacilli illness medicine is by above-mentioned walnut grouts polyphenol purified and pharmaceutically acceptable load
Body forms.
8. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 7,
It is characterized in that the pharmaceutically acceptable carrier includes filler, adhesive, disintegrant, lubricant, suspending agent, wetting
One kind or pharmaceutically acceptable any combination in agent, solvent, surfactant, flavouring.
9. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 7,
It is characterized in that the treatment intestinal bacilli illness medicine includes the core comprising walnut grouts polyphenol purified and includes methyl
It is acrylic copolymer, HP-55, acetic acid hydroxypropyl methylcellulose succinate, CAP, poly-
The enteric coating layer of the component of polymer of one kind or any combination in vinyl acetate phthalate ester.
10. walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine according to claim 9,
It is characterized in that the component of polymer in the enteric coating layer is by methacrylic acid and selected from methyl acrylate, acrylic acid second
The methacrylic acid copolymer that the monomer of one kind or any combination in ester, methyl methacrylate is formed.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710871251.0A CN107595934A (en) | 2017-09-25 | 2017-09-25 | A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710871251.0A CN107595934A (en) | 2017-09-25 | 2017-09-25 | A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107595934A true CN107595934A (en) | 2018-01-19 |
Family
ID=61057820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710871251.0A Pending CN107595934A (en) | 2017-09-25 | 2017-09-25 | A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107595934A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114404473A (en) * | 2021-12-21 | 2022-04-29 | 云南中医药大学 | Walnut meal polyphenol with lipid-lowering effect and preparation method and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102845572A (en) * | 2012-08-30 | 2013-01-02 | 陈朝银 | Walnut tea based on walnut kernel polyphenol and preparation of drink thereof |
| CN105601698A (en) * | 2015-12-23 | 2016-05-25 | 浙江农林大学 | Method for extracting saponins from Carya illinoensis cakes and husks of Carya illinoensis |
-
2017
- 2017-09-25 CN CN201710871251.0A patent/CN107595934A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102845572A (en) * | 2012-08-30 | 2013-01-02 | 陈朝银 | Walnut tea based on walnut kernel polyphenol and preparation of drink thereof |
| CN105601698A (en) * | 2015-12-23 | 2016-05-25 | 浙江农林大学 | Method for extracting saponins from Carya illinoensis cakes and husks of Carya illinoensis |
Non-Patent Citations (8)
| Title |
|---|
| YULAN LI，ET AL: "Preventive effect of pressed degreased walnut meal extracts on T2DM rats by regulating glucolipid metabolism and modulating gut bacteria flora.", 《JOURNAL OF FUNCTIONAL FOODS》 * |
| 史金凤，等: "核桃仁酚性成分及其生物活性研究进展", 《中成药》 * |
| 梁杏，等: "核桃饼粕多酚纯化工艺及其抗氧化活性的研究", 《中国酿造》 * |
| 梁杏，等: "液态发酵核桃饼粕的初步研究", 《中国酿造》 * |
| 梁杏: "核桃饼粕多酚提取纯化及其抗氧化和降脂活性初步研究", 《中国优秀硕士学位论文全文数据库医药卫生科技辑》 * |
| 樊永波，等: "核桃饼粕对大鼠学习、记忆和抗氧化功能的影响", 《食品科学》 * |
| 金子纯，等: "核桃饼粕蛋白质及其开发利用", 《食品与发酵工业》 * |
| 陈杏云，等: "高脂饮食对菌群人源化小鼠肠道菌群结构的影响", 《食品科学》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114404473A (en) * | 2021-12-21 | 2022-04-29 | 云南中医药大学 | Walnut meal polyphenol with lipid-lowering effect and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105169203B (en) | A kind of Fructus Amomi extract and application thereof | |
| CN102836188A (en) | Folium microcotis total flavone extract and preparation method and application thereof | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN101664180B (en) | Health-care nutritional complexing agent with health effect and preparation method thereof | |
| CN105983016B (en) | A pharmaceutical composition containing silybin | |
| CN104055947B (en) | A kind of Chinese medicine composition and preparation method containing grape extract | |
| CN107595934A (en) | A kind of walnut grouts polyphenol purified is preparing the purposes in treating intestinal bacilli illness medicine | |
| CN103610675A (en) | Application of jateorhizine in pharmacy | |
| CN105106300A (en) | Use of cyclocarya paliurus extract in preparation of drug for preventing and treating non-alcoholic fatty liver disease | |
| CN109045070A (en) | A kind of composition for preventing and treating non-alcoholic fatty liver disease | |
| CN110074392A (en) | A kind of Antialcoholic liver-protecting nourishing the stomach shield intestines composition and preparation method thereof | |
| WO2019100843A1 (en) | Enteromorpha prolifera polysaccharide composite blood lipid-lowering health care product and preparation method therefor | |
| CN107961293A (en) | A kind of sea-buckthorn tomato piece and preparation method thereof | |
| CN104435072B (en) | A kind of extract and preparation method thereof with auxiliary hyperglycemic, reducing blood lipid | |
| CN103156106A (en) | Lipid lowering and liver protecting drug or health food prepared by active ingredients of fructus schisandrae chinensis and preparation method | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| CN110840950A (en) | Application of Russian tea and/or Russian tea extract in preparation of medicines for preventing and treating non-alcoholic liver disease and/or non-alcoholic liver injury | |
| CN105360787A (en) | Health food and preparation method thereof | |
| CN109602893A (en) | A kind of composition and its preparation improving hepatic injury and organism fatigue | |
| CN113694105B (en) | Composition with blood fat reducing function and application thereof | |
| CN105560310B (en) | Pharmaceutical application of Symplocos chinensis polysaccharide and composition thereof | |
| CN104138488B (en) | A kind of pharmaceutical composition of reducing blood lipid and its application | |
| CN109549988A (en) | A kind of oil tea reducing blood lipid nano compound preparation and its preparation method and application | |
| WO2013155997A1 (en) | Blood lipid-regulating red yeast ligusticum chuanxiong pharmaceutical composition and preparation method therefor | |
| CN112315939B (en) | Capsella bursa-pastoris seed oil microcapsule for reducing blood fat and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180119 |